1. Home
  2. IZEA vs PRLD Comparison

IZEA vs PRLD Comparison

Compare IZEA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IZEA Worldwide Inc.

IZEA

IZEA Worldwide Inc.

SELL

Current Price

$4.79

Market Cap

69.1M

ML Signal

SELL

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$1.98

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZEA
PRLD
Founded
2006
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.1M
69.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
IZEA
PRLD
Price
$4.79
$1.98
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
126.5K
405.7K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,176,492.00
$10,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.12
250.00
52 Week Low
$1.68
$0.61
52 Week High
$5.86
$4.22

Technical Indicators

Market Signals
Indicator
IZEA
PRLD
Relative Strength Index (RSI) 45.35 60.34
Support Level $4.72 $1.60
Resistance Level $5.08 $1.72
Average True Range (ATR) 0.17 0.16
MACD -0.03 0.05
Stochastic Oscillator 18.73 89.54

Price Performance

Historical Comparison
IZEA
PRLD

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: